Alzheimer's Disease Education and Referral Center

Alzheimer’s Disease & Related Dementias (AD+ADRD) Research Implementation Milestone Database

This database is a web-based tool for tracking funding initiatives and activities developed by the NIH and other funding organizations supporting Alzheimer's Disease  and AD-Related Dementias (AD+ADRD) aimed at achieving the research milestones associated with the first goal of the National Plan to Address Alzheimer's: to treat and prevent Alzheimer's by 2025. The purpose of this new data resource is to facilitate strategic coordination and collaborations among funding organizations in order to maximize the public health impact of the collective investment in AD+ADRD research.

The milestones represent a research framework detailing specific steps and success criteria for the NIH and other stakeholders towards the development of effective treatments for AD+ ADRD. They were developed based on recommendations from the Strategic Research Planning Summits: NIH AD Research Summits 2012 and 2015 and the NIH ADRD Research Summits 2013 and 2016 put forward by over 200 leading academic and industry experts, innovators and public advocates. The milestones span the entire AD+ADRD research landscape including basic, translational, clinical and health services research and serve as the basis for the development of theNIH Alzheimer's Disease Bypass Budget.

The database can be searched based on research implementation areas and/or the Common Alzheimer's Disease Research Ontology (CADRO) categories. For each milestone, in addition to listing new funding initiative and programs, the database links to relevant projects funded by over 35 funding organizations, members of the International Alzheimer's Disease Research Portfolio (IADRP) .

Estimated Startsort descending Research Implementation Area CADRO Category Milestone
2013 Portfolio Analysis Tools and Methods F. Research Resources 15.A: Develop a common Alzheimer’s disease research ontology...
2013 Drug Development - Novel Targets C. Translational Research and Clinical Intervention 6.A: Establish a searchable, open access research database that contains all clinical, biomarker, and epidemiological data, and related genotypes and phenotypes from existing genetic studies…
2013 Drug Development - Novel Targets A. Molecular Pathogenesis and Physiology of Alzheimer's Disease 6.B: Establish a consortium of genetics and genomics experts to develop and execute a large scale sequencing project to analyze the genomes of a large number of well characterized individuals…
2013 Public Private Partnerships G. Consortia and Public Private Partnerships 14.A: Convene an advisory meeting focused on facilitating public-private partnerships aimed at accelerating the development and test of effective therapies for AD treatment and prevention...
2014 Public Private Partnerships G. Consortia and Public Private Partnerships 14.B: Convene meetings of the working groups for (i) Rapid Data Sharing and Analysis, (ii) Enabling Bidirectional Translation in AD drug development, (iii) Eliminating IP barriers for Target Validation...
2014 Biomarkers B. Diagnosis, Assessment and Disease Monitoring 9.H: Launch research programs to develop and validate sensitive neuropsychological and behavioral assessment measures...
2014 Translational Infrastructure and Capabilities F. Research Resources 4.F: Create a network of translational centers that bring together expertise and technology needed for integration of multi-modal data analysis, mathematical modeling and empirical testing and apply a systems biology/systems pharmacology approach…
2014 Biomarkers B. Diagnosis, Assessment and Disease Monitoring 9.I: Develop and test methods for the standardization of immunoassays and mass-spectrometry/single reaction monitoring assay...
2014 Translational Infrastructure and Capabilities C. Translational Research and Clinical Intervention 4.H: Create a National IRB...
2014 Trial Design C. Translational Research and Clinical Intervention 10.B: Establish a working group to identify standard outcome measures necessary for data comparisons across secondary prevention trials...

Pages